Alejandro Arana

Alejandro Arana

Auto-generated profile, based on publicly available information

Alejandro Arana

Department of Epidemiology RTI Health Solutions Barcelona Spain

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 August 2010 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
AAAlejandro Arana
Alejandro Arana
CWCharles E. Wentworth
Charles E. Wentworth
JAJosé L. Ayuso-Mateos
José L. Ayuso-Mateos
FAFelix M. Arellano
Felix M. Arellano
A previous meta-analysis of data from clinical trials showed an association between antiepileptic drugs and suicidality (suicidal ideation, behavior, or both). We used observational data to examine the association between the use or nonuse of antiepileptic drugs and suicide-related events (attempted suicides and completed suicides) in patients with epilepsy, depression, or bipolar disorder.

9 June 2010 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
AAA. Arana
A. Arana
CWC.E. Wentworth
C.E. Wentworth
CFC. Fernández-Vidaurre
C. Fernández-Vidaurre
RSR.G. Schlienger
R.G. Schlienger
ECE. Conde
E. Conde
FAF.M. Arellano
F.M. Arellano

1 May 2009 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
FAFelix M. Arellano
Felix M. Arellano
AAAlejandro Arana
Alejandro Arana
CWCharles E. Wentworth
Charles E. Wentworth
CFCarlos Fernández-Vidaurre
Carlos Fernández-Vidaurre
RSRaymond G. Schlienger
Raymond G. Schlienger
ECEulogio Conde
Eulogio Conde

1 March 2018 in Epidemiology
Verified
Journal Article
Open access
PDF file
AMAndrea V. Margulis
Andrea V. Margulis
JFJoan Fortuny
Joan Fortuny
JKJames A. Kaye
James A. Kaye
BCBrian Calingaert
Brian Calingaert
MRMaria Reynolds
Maria Reynolds
AAAlejandro Arana
Alejandro Arana
In the United Kingdom, hospital or cancer registry data can be linked to electronic medical records for a subset of general practices and years. We used Clinical Practice Research Datalink data (2004-2012) from patients treated for overactive bladder. We electronically identified provisional cases of 10 common cancers in General Practitioner Online Database data and validated them by medical profile review. In practices with linkage to Hospital Episodes Statistics and National Cancer Data Repository (2004-2010), we validated provisional cancer cases against these data sources. This linkage also let us identify additional cancer diagnoses in individuals without cancer diagnosis records in the General Practitioner Online Database. Among 50,840 patients, 1,486 provisional cancer cases were identified in the General Practitioner Online Database for 2004-2012. Medical profile review confirmed 93% of 661 cases in non-linked practices (range, 100% of non-Hodgkin lymphomas and uterine cancer to 77% of skin melanomas) and 96% of 825 cases in linked practices (100% of kidney and uterine cancers to 92% of melanomas). In the subset of linked practices, for 2004-2010, 720 cases were confirmed, of which 68% were identifiable in the General Practitioner Online Database (range, 90% of breast to 36% of kidney cancers). Most cases of cancer identified electronically in the General Practitioner Online Database were confirmed. A substantial proportion of cases, especially of cancer types not typically managed by general practitioners, would be missed without Hospital Episodes Statistics and National Cancer Data Repository data (and are likely missed in non-linked practices). European Union electronic Register of Post-Authorisation Studies (EU PAS Registry) number EUPAS5529, http://www.encepp.eu/encepp/viewResource.htm?id=11107 This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

1 April 2002 in Acta Haematologica
Verified
Journal Article
Closed access
PDF file
JCJ. Jaime Caro
J. Jaime Caro
AWAlexandra Ward
Alexandra Ward
TGTraci Craig Green
Traci Craig Green
KHKrista Huybrechts
Krista Huybrechts
AAAlejandro Arana
Alejandro Arana
AEAndroulla Eleftheriou
Androulla Eleftheriou
Objective: To describe the burden of thalassemia major and its treatment, in terms of prevalence of iron-overload-related complications, direct and indirect costs, and the patient’s physical and social well-being. Methods: From October 1999 to May 2000 a survey of patients with thalassemia major was conducted in ten countries: Cyprus, Egypt, Greece, Hong Kong, India, Iran, Italy, Jordan, Taiwan, and the United States. Results: 1,888 questionnaires (65%) were returned. The responses suggest that nowadays patients begin blood transfusions, and most use desferrioxamine (84.8%), but iron-related complications, including life-threatening ones such as heart disease, are still common. Conclusions: There remains a need to improve the management of thalassemia, as many patients with iron-related complications experience physical and social limitations.

8 September 2015 in Drug Safety
Verified
Journal Article
Open access
PDF file
AAAlejandro Arana
Alejandro Arana
CJCatherine B. Johannes
Catherine B. Johannes
LMLisa J. McQuay
Lisa J. McQuay
CVCristina Varas-Lorenzo
Cristina Varas-Lorenzo
DFDaniel Fife
Daniel Fife
KRKenneth J. Rothman
Kenneth J. Rothman
Introduction Epidemiological studies have linked domperidone use with serious cardiac arrhythmias, including sudden cardiac death, but data on age, dose, and duration of use are limited. Objectives The aim of this study was to assess the risk of out-of-hospital sudden cardiac death associated with domperidone use versus proton pump inhibitors (PPIs), metoclopramide, or non-use of all three medications, and to evaluate the risk of sudden cardiac death in relation to age and domperidone dose. Methods This was a population-based case-control study nested in a cohort of subjects aged ≥2 years in the Clinical Practice Research Datalink with one or more prescriptions for domperidone, any PPI, or metoclopramide from 2005 to 2011. Out-of-hospital sudden cardiac death was assessed by linkage with Hospital Episode Statistics and death certificates. Controls were matched on age, sex, and medical practice. The risk of sudden cardiac death in domperidone users versus risk in users of PPIs or metoclopramide was evaluated with multivariable conditional logistic regression; case-crossover analysis addressed possible residual confounding. Results From the study cohort (n = 681,104), 3239 sudden cardiac death cases were matched to 12,572 controls. The adjusted odds ratio (95 % confidence interval) for sudden cardiac death with current use of domperidone alone was 1.71 (0.92–3.18) versus non-use of study medications, 1.26 (0.68–2.34) versus current PPI use, and 0.40 (0.17–0.94) current metoclopramide use. The adjusted odds ratio (95 % confidence interval) relative to exposure to no study drug for domperidone >30 mg/day (eight cases, five controls) was 3.20 (0.59–17.3) and 1.65 (0.89–3.07) for age ≥61 years (27 cases, 49 controls). The odds ratio (95 % confidence interval) was 3.17 (1.72–5.83) for within-person periods of domperidone use versus non-use in the case-crossover analysis. Conclusions Compared with non-use of any study drug, current domperidone use was associated with sudden cardiac death in nested case-control and case-crossover analyses, with a suggestion of higher risk in older persons and users of higher daily doses.